Congenital Anomaly of Pregnant Women Clinical Trial
Official title:
The Role of Placental Myeloid Cells During Gestation, Labor and Disease
Immature myeloid cells (IMCs) that are generated in the bone marrow, and differentiate into
mature granulocytes, macrophages and dendritic cells (DCs) in the steady state. Recently, it
was demonstrated that the IMC population expands in malignancy, both in animal models and in
humans. These cells were described as immunosuppressants but have also been shown to promote
tumor angiogenesis. Accordingly, IMCs were also found to take part in the burn injury wound
healing process and other pathologies that involve angiogenesis. It was shown in the
investigators' laboratory, that a very similar population of IMCs populates the mouse and
human placenta, and that these cells actively promote angiogenesis.
Dendritic cells (DCs) that can differentiate from IMCs, are antigen presenting cells (APCs)
that initiate and coordinate the innate and adaptive immune responses. DCs can take up a
diverse array of antigens and present them to T cells as peptides bound to MHC products.
These antigen-specific responses are critical for resistance to infection and tumors.
Conversely, DCs have roles in autoimmunity, transplant rejection and immunological
tolerance. In the reproductive system, DCs were shown to account for 5%-10% of all
hematopoietic cells in the uterine decidua at the embryonic implantation site. They were
shown to promote angiogenesis during early pregnancy, especially during implantation. Very
little is known about their function in the placenta and in the latter part of pregnancy
when significant angiogenesis takes part.
The investigators' preliminary mouse experiments and human data, demonstrate a shift in
IMC/DC populations with the development of the placenta. The investigators hypothesize that
this population shift may contribute to the labor and delivery process.
The investigators' aim is to understand the role of these myeloid cell populations during
pregnancy, to characterize their phenotype and try to shed light on the cellular and
molecular mechanisms of pregnancy complications, such as preeclampsia, pre-term labor,
intrauterine growth restriction, etc.
| Status | Not yet recruiting |
| Enrollment | 100 |
| Est. completion date | April 2015 |
| Est. primary completion date | April 2015 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years to 45 Years |
| Eligibility |
Inclusion Criteria: - pregnant women Exclusion Criteria: |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Israel | Hillel Yaffe Medical Center | Hadera |
| Lead Sponsor | Collaborator |
|---|---|
| Hillel Yaffe Medical Center | Technion, Israel Institute of Technology |
Israel,